So, the VAT tax is based on consumption of manufactured goods and services, but what is it used for? Each nation is free to decide just how to allocate its tax revenues. In many countries that have such a tax, the funds are often used to pay for a portion of a nation's health care, usually for the entire population. This structure constrains health-care revenues to grow somewhat in proportion to the consumption of goods and services in the economy. The VAT tax can be high in countries that use it -as much as 30% of the purchase price of a manufactured item.
It is true that, in the United States, we do not pay such a tax on goods and services, nor do we pay a tax on each component of health-care delivery, but consider this. Many components of the delivery system (e.g., drugs, devices, construction, salaries, insurance, patient debt) depend substantially on borrowed money. Along with borrowed money comes the fee to service the debt. These fees on debt add end-to-end and the result is higher health-care costs due to debt service. Instead of the government (as would be the case in a VAT tax), large financial institutions are usually the recipients of these debt service fees and the ones that benefit substantially from the current system. The large financial institutions then use these funds to purchase government bond reserves, provide additional loans often for various types of health-care system loans (such as highly profitable student loans), and of course provide substantial pay packages to its officers.
As an example, of the 10 wealthiest companies with massive debt in the US, two are drug companies, Pfizer and Amgen (http://americasmarkets.usatoday.com/2015/02/05/10-rich-companies-with-tons-of-debt/).
Additionally, much of US health-care debt is owed directly by US patientshttp://health.usnews.com/health-news/health-wellness/articles/2014/12/11/how-couldamerica-get-its-medical-debt-problem-in-check.
I will leave it to you to investigate the debt carried by device manufacturers, the debt held by insurance companies, and the debt accrued by the intermediate and large health-care systems. All of the servicing of this debt is ultimately carried by the patient as a consumer of healthcare services.
Another insight and an essential factor to consider is the anti-trust exemption enjoyed by insurance companies, as specified in the 1945 McCarran-Ferguson Act.
The federal law does several things:
• It allows insurers to share related information that lowers costs of doing business. This includes joint development of insurance forms and the sharing of loss data to help with policy pricing; • It provides insurers with a narrow and limited exemption from federal antitrust laws as long as the activity is state-regulated; • It explicitly empowers states to regulate and tax insurance (See https://www.ohioinsurance.org/factbook2001/chapter6/chapter_6k.htm).
The R Street Institute offers the following thoughts on McCarran-Ferguson (http://www. rstreet.org/wp-content/uploads/2015/11/RSTREET46.pdf):
"While explicit price-and-wage controls largely have fallen by the wayside in most industries (outside of natural monopolies like utilities), pure rate regulation remains commonplace in insurance. Some degree of rating and underwriting regulation persists in nearly every one of the 50 states. This is, to a large degree, a relic of an earlier time, when nearly all insurance rates and forms were established collectively by industry-owned rate bureaus, as individual insurers generally were too small to make credible actuarial projections.
"McCarran-Ferguson charged states with reviewing the rates submitted by these bureaus because of concerns of anticompetitive collusion. With the notable exception of North Carolina, rate bureaus no longer play a central role in most personal lines markets, and many larger insurers now establish rates using their own proprietary formulas, rather than relying on rate bureau recommendations."
Here are some thoughts from the Alliance for Responsible Legal Funding (http://arclegalfunding.org/the-big-insurance-equation-for-hypocrisy/): "… in 2010 the sitting Assistant Attorney General of the Antitrust Division at the Department of Justice, Christine Varney, testified before Congress that the exemption is 'very expansive' with regard to anything that falls within the business of insurance. This includes premium pricing and market allocations.
"Varney said that insurance companies are 'virtually always found immune' of the 'most egregiously anticompetitive claims, such as naked agreements fixing price or reducing coverage' due to their antitrust exemption.
"Similarly, the acting Assistant Attorney General from the Office of the Attorney General for New York, Elinor Hoffmann, asked Congress in 2006 to reexamine McCarran-Ferguson Act because it 'precludes federal antitrust enforcement of serious anticompetitive conduct' in insurance. She referenced her department's investigations into 'new and pervasive instances of abuse' in the insurance sector, including bid-rigging and questionable brokerage fees."
In fairness, this is a very complex issue, and I am sure you would anticipate the insurance industry has a great deal to say about why tampering with or repealing the McCarran-Ferguson Act would raise rather than lower health-care costs (http://healthcarereform.procon.org/view. answers.php?questionID=001890).
The Insurance Information Institute would very much like for you to see what they have to say about this: http://www.iii.org/article/antitrust-law-and-insurance.
So I invite you to come to this topic with critical thinking and skepticism and see what conclusion you reach.
The final thought I have is that in the United States, the pharmaceutical industry has achieved a substantial benefit from the Federal Government. CMS is apparently barred from negotiating Medicare prescription-drug prices in bulk (http://carleton.ca/sppa/wp-content/uploads/MirrorMirror-Medicare-Part-D-Released.pdf).
It certainly does not seem to make any sense that the Veterans Administration and Medicaid can negotiate drug prices in bulk, but Medicare cannot. The advantage to the drug companies is estimated at tens of billions of dollars per year and at the expense of higher health-care costs ultimately for everyone who pays taxes and hopes someday to receive Medicare benefits.
Yes, we as medical physicists in the US enjoy higher salaries and a certain prestige. Additionally, our health-care benefits are usually quite generous, especially if associated with our employing institutions. However, the path we are on is unsustainable. The growth in health-care costs, if not checked, will eventually exceed the ability of the US population to service this debt. (See: www.forbes.com/sites/toddhixon/2012/02/09/ the-u-s-does-not-have-a-debt-problem-it-has-a-health-care-cost-problem/#61c1c3947f6f).
There is a certain and inevitable adjustment coming to US health care, and I do not believe our profession will be exempt. I submit we should educate ourselves and develop plans to best position the profession in the stormy seas that will characterize the competition for health-care dollars in the immediate years ahead.
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